Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dennis J. Cada is active.

Publication


Featured researches published by Dennis J. Cada.


Hospital Pharmacy | 2004

Furosemide(nebulized): Dyspnea in cancer patients

Joyce A. Generali; Dennis J. Cada

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to [email protected].


Hospital Pharmacy | 2012

Ascorbic Acid: Prevention of Contrast-Induced Nephropathy

Joyce A. Generali; Dennis J. Cada

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to [email protected].


Hospital Pharmacy | 2011

Off-Label Drug Uses - Nitroglycerin (Ointment): Low Bone Density or Osteoporosis in Postmenopausal Women

Joyce A. Generali; Dennis J. Cada

This Hospital Pharmacy feature is extracted from Off-Label Drug Pacts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Pacts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to [email protected].


Hospital Pharmacy | 2004

Pentoxifylline : Aphthous Stomatitis

Joyce A. Generali; Dennis J. Cada

Recurrent aphthous stomatitis(RAS) is a common oral diseasewithout an exact etiology. Thedevelopment of lesions has beenassociated with trauma, smoking,stress, food hypersensitivities, andinfectious factors. RAS may be cat-egorized as minor or major. Minor RAS is common andusually associated with lesions inthe buccal or labial mucosa, lateraltongue, or the floor of the mouth.Lesions may range from a singlewound up to 10, typically less than1 cm in size. In general, minor RASis self-limiting, usually lasting only1 to 2 weeks with mild-to-moder-ate pain and rarely causing scar-ring. In contrast, major RAS is lesscommon and typically involves thelabial mucosa, soft palate, andoropharynx. While the number oflesions may be fewer, they are typi-cally greater in size (greater than 1cm) and cause severe pain that lastsfrom 2 to 8 weeks. Major RAS ismore commonly observed inpatients with HIV or gastrointesti-nal disease (Eisen 2001).Because no conclusive evidencehad been clearly identified for RAS,therapy is designed to suppress andprovide symptomatic relief. In themajority of patients, symptomaticrelief of RAS can be achieved withtopical corticosteroids alone, withother immunomodulatory topicalagents, or by combination therapy.Although these products mayreduce the pain and inflammation,most benefits are modest and workbest in minor RAS.


Hospital Pharmacy | 2004

Off-label drug uses. Sildenafil (topical): Anal fissures

Joyce A. Generali; Dennis J. Cada

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to [email protected].


Hospital Pharmacy | 2004

Gabapentin: Nausea, Chemotherapy-Induced

Joyce A. Generali; Dennis J. Cada

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to [email protected].


Hospital Pharmacy | 2003

Zoledronic acid: Postmenopausal osteoporosis

Joyce A. Generali; Dennis J. Cada

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to [email protected].


Hospital Pharmacy | 2003

Gabapentin: Neuropathy (diabetic)

Joyce A. Generali; Dennis J. Cada

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to [email protected].


Hospital Pharmacy | 2003

Lansoprazole: Alternate Day Dosing

Joyce A. Generali; Dennis J. Cada

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to [email protected].


Hospital Pharmacy | 2003

Alteplase: Pleural effusion (parapneumonic)

Joyce A. Generali; Dennis J. Cada

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to [email protected].

Collaboration


Dive into the Dennis J. Cada's collaboration.

Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge